Services
Ready-to-use TrueCardium® organoids
Custom TrueCardium® disease modeling
Custom TrueCardium® disease modeling
Ready-to-use healthy and diseased (selected models) TrueCardium® organoids for in-house studies.
Custom TrueCardium® disease modeling
Custom TrueCardium® disease modeling
Custom TrueCardium® disease modeling
Custom disease-model development: including cellular and molecular characterization, multi-omics profiling and compound screening.
Compound screening in TrueCardium® organoids
GENISYST®: Complex disease heterogeneity modeling
GENISYST®: Complex disease heterogeneity modeling
Cardiotoxicity screening and efficacy validation.
GENISYST®: Complex disease heterogeneity modeling
GENISYST®: Complex disease heterogeneity modeling
GENISYST®: Complex disease heterogeneity modeling
GENISYST implements complex disease heterogeneity patterns in TrueCardium® and facilitates multiplexed gene family/cluster phenotypic analysis.
Key Applications
Cardiotoxicity Screening
Disease Modeling & Mechanistic Studies
Disease Modeling & Mechanistic Studies
Early detection of adverse liabilities with structural and functional fidelity.
Disease Modeling & Mechanistic Studies
Disease Modeling & Mechanistic Studies
Disease Modeling & Mechanistic Studies
Capture human pathophysiology that 2D cultures or animal models often miss.
Personalized Medicine & Patient Stratification
Personalized Medicine & Patient Stratification
Personalized Medicine & Patient Stratification
Organoids generated from patient-specific iPSCs allow drug-response testing across genetic backgrounds.
Advanced Analytics
Personalized Medicine & Patient Stratification
Personalized Medicine & Patient Stratification
Functional read outs, electrophysiology and omics (transcriptomics, proteomics, metabolomics) for high-resolution mechanistic insight.
Genetic & Stress Induced Disease Modeling
Cardiotoxicity
Diabetic Cardiomyopathy / HFpEF
Diabetic Cardiomyopathy / HFpEF
Modeling NCE, anthracycline and other drug-related cardiac-tissue toxicity.
Diabetic Cardiomyopathy / HFpEF
Diabetic Cardiomyopathy / HFpEF
Diabetic Cardiomyopathy / HFpEF
Lipid accumulation, oxidative stress, and fibrotic remodeling.
Inflammation-Driven Remodeling
Diabetic Cardiomyopathy / HFpEF
Inflammation-Driven Remodeling
Immune-triggered structural changes (e.g., LPS, cytokine exposure, CHIP).
Ischemic Injury
Inflammation-Driven Remodeling
Hypoxia-induced damage mimicking myocardial infarction and heart failure.
Mitochondrial myopathies
Energy-metabolism defects leading to dilated-cardiomyopathy phenotypes.
Rare Disease
Modeling Rare and Orphan diseases for drug discovery and validation.
TrueCardium® Readouts
Viability / Cell Death
Viability / Cell Death
Viability / Cell Death
CellTiter-Glo® / Alamar Blue
LDH assay
hsTNT assay
Secreted Reporters
Contractility
Viability / Cell Death
Viability / Cell Death
Calcium flux assays
Contractilty assays
Metabolism
Viability / Cell Death
Cell Proliferation
SeaHorse metabolic flux assays
Intra- / Extra- cellular oxygenation assays
Lactate assay
JC10 assay
Cell Proliferation
Cellular and Molecular Profiling
Cell Proliferation
EdU / Ki-67
Phospho-histone H3
Aurora B (late telophase)
Secreted Reporters
Cellular Senescence
Cellular and Molecular Profiling
Cellular and Molecular Profiling
SA-ß-gal activity
p16INK4a promoter reporter
Cellular and Molecular Profiling
Cellular and Molecular Profiling
Cellular and Molecular Profiling
RNAseq / single-cell RNAseq
Spatial transcriptomics
Proteomics
Metabolomics
Publications
